Drug Trial Radar · NCT06100744
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 8, 2024
Primary completion
Sep 2026
Study completion Oct 2028
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Oct 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. PsA that begins before a patient's 16th birthday is called juvenile PsA (jPsA).This study will evaluate how safe risankizumab is for the treatment of psoriatic arthritis and to assess change in disease symptoms. Risankizumab is being studied for the treatment of jPsA and adalimumab is approved for the treatment of jPsA. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to receive adalimumab. Approximately 40 juvenile participants with jPsA will be enrolled at approximately 30 sites worldwide. Participants will receive risankizumab and adalimumab as subcutaneous (SC) injections based on body weight. At the start of Period 1, participants are randomized to receive risankizumab or adalimumab for 24 weeks. Participants who respond to the study treatment received in Period 1, will continue to receive the same treatment in Period 2 for another 100 weeks. Those with worsening jPsA symptoms in Period 2 will be withdrawn from the study. Participants who receive adalimumab are followed for safety for 70 days after the last study treatment. Participants who receive risankizumab are followed for 140 days after the last study treatment. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Juvenile Psoriatic Arthritis
Interventions
AdalimumabDrug
SC Injection
RisankizumabDrug
Subcutaneous (SC) Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants who Achieve >= 30% Improvement in Juvenile Idiopathic Arthritis American College of Rheumatology Response Criteria (JIA-ACR 30)Time frame: Up to 24 Weeks
- Number of Participants with Adverse Events (AEs)Time frame: Up to Week 144
Locations
34 sites in 9 countries. Site status is shown where the registry gives one.
Arkansas Children's Hospital /ID# 258776
Little Rock, Arkansas · Recruiting
Childrens National Medical Center /ID# 259284
Washington D.C., District of Columbia · Recruiting
Joe Dimaggio Children's Hospital Hollywood /ID# 260634
Hollywood, Florida · Recruiting
All X Ray Diagnostic Services Corp /ID# 278523
Miami, Florida · Recruiting
Indiana University Health Riley Hospital for Children /ID# 259067
Indianapolis, Indiana · Recruiting
M Health Fairview University of Minnesota Medical Center - West Bank /ID# 260111
Minneapolis, Minnesota · Recruiting
Columbia University Medical Center /ID# 262587
New York, New York · Recruiting
Boston Childrens Health Physicians /ID# 258061
Valhalla, New York · Recruiting
University of North Carolina - Children's Hospital /ID# 259286
Chapel Hill, North Carolina · Recruiting
MetroHealth Medical Center /ID# 262377
Cleveland, Ohio · Recruiting
Cleveland Clinic - Cleveland /ID# 276655
Cleveland, Ohio · Recruiting
Child Neurology Consultants of Austin /ID# 260562
Austin, Texas · Recruiting
Monash Health - Monash Medical Centre - Clayton /ID# 260255
Clayton, Victoria, Australia · Recruiting
Alberta Children's Hospital /ID# 257880
Calgary, Alberta, Canada · Recruiting
British Columbia Children and Women's Hospital and Health Centre /ID# 257884
Vancouver, British Columbia, Canada · Recruiting
Hospital for Sick Children /ID# 257879
Toronto, Ontario, Canada · Recruiting
Chu Bordeaux - Hopital Pellegrin /ID# 258729
Bordeaux, New Aquitaine, France · Recruiting
AP-HP - Hopital Bicetre /ID# 258728
Le Kremlin-Bicêtre, Paris, France · Recruiting
Helios Klinikum Berlin - Buch /ID# 268803
Berlin, Germany · Recruiting
Hamburger Zentrum fuer Kinder- und Jugendrheumatologie /ID# 259104
Hamburg, Germany · Recruiting
Asklepios Klinik Sankt Augustin /ID# 259106
Sankt Augustin, North Rhine-Westphalia, Germany · Recruiting
Azienda Ospedaliero Universitaria Meyer /ID# 258587
Florence, Firenze, Italy · Recruiting
ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO /ID# 276753
Milan, Milano, Italy · Recruiting
Ospedale Pediatrico Bambino Gesu /ID# 258869
Rome, Roma, Italy · Recruiting
Malopolskie Badania Kliniczne /ID# 258777
Cracow, Lesser Poland Voivodeship, Poland · Recruiting
SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi /ID# 258785
Lodz, Łódź Voivodeship, Poland · Recruiting
Uniwersytecki Szpital Dzieciecy w Lublinie /ID# 258781
Lublin, Lublin Voivodeship, Poland · Recruiting
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. /ID# 277050
Warsaw, Masovian Voivodeship, Poland · Recruiting
Centrum Zdrowia Dziecka i Rodziny im Jana Pawla II w Sosnowcu /ID# 277058
Sosnowiec, Silesian Voivodeship, Poland · Recruiting
Hospital Universitario y Politecnico La Fe /ID# 257567
Valencia, Spain · Recruiting
Hospital Sant Joan de Deu /ID# 257568
Esplugues de Llobregat, Barcelona, Spain · Recruiting
University Hospitals Bristol and Weston NHS Foundation Trust /ID# 258847
Bristol, United Kingdom · Recruiting
Alder Hey Children's NHS Foundation Trust /ID# 262770
Liverpool, United Kingdom · Recruiting
Sheffield Children's Hospital NHS Foundation Trust /ID# 258848
Sheffield, England, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.